Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06958107 · ClinicalTrials.gov registry record
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
A clinical trial of Sarcoma, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 300
- Enrollment target
- 2
- Study locations
NCT06958107 is a study of Sarcoma that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 300 participants, below the 919-participant average among 122 other Sarcoma trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06958107, a study of Sarcoma, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).
Conditions Studied
Interventions
- OTHER Non-Metastatic and Resectable
- OTHER Metastatic and Un-resectable
- OTHER No evidence of disease, under surveillance
- OTHER ALT or WDLS
Study Locations (2)
North Carolina
- Levine Cancer Institute - Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-08-21 |
| Est. Completion | 2030-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06958107
The ClinicalTrials.gov registry entry for NCT06958107 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 919-participant average among 122 other Sarcoma trials with a reported enrollment target (67% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which Non-Metastatic and Resectable is the first listed.
NCT06958107 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06958107 about?
NCT06958107 is a clinical study titled "LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients". The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).
What is the current status of trial NCT06958107?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-08-21. Estimated completion is 2030-01.
What conditions does trial NCT06958107 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT06958107?
The interventions under investigation include: Non-Metastatic and Resectable (OTHER), Metastatic and Un-resectable (OTHER), No evidence of disease, under surveillance (OTHER), ALT or WDLS (OTHER).
Who is sponsoring clinical trial NCT06958107?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06958107 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Enhanced Recovery After Surgery in Extremity Sarcoma
RECRUITING · NA
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.